# Test Criteria: 170.315.a.4 – Drug-drug, Drug-allergy Interaction Checks for CPOE

|  |  |
| --- | --- |
| **Testing Result** |  |
| Participant and Product-with-version |  |
| Setting (Ambulatory or Inpatient) |  |
| Test Proctor |  |
| Test Date |  |
| Test Result | Pass:  Fail:  No Attempt: |
| Error Description (if applicable) |  |
| Modifications to Product Under Test |  |
| Additional Software Used |  |
| Additional Proctor Notes |  |

### Overview

In this document you will find:

* [Test Data and Test Tools](#_Test_Data_and)
* [Standards Support](#_Demonstrate_Standards_Support)
* [Drummond Test Report (Instructions, Expected Results, Points to Remember)](#_DTR_170.315(a)(4)(i)_–)
* [Test Procedures](#_DTR_170.315(a)(4)(i)_–)
* [Appendix A: Testing Guide](#_Appendix_A:_Testing)
* [Appendix B: ONC Criteria](#_Appendix_B:_ONC)

### Version of ONC Test Method

1.0

### Scope of Proctoring Sheet

The ONC test method associated with this criterion is the only approved test method for EHR Meaningful Use certification. This Proctoring Sheet is not a replacement test method but a test procedure document for performing the ONC test method and recording the results. Proctoring Sheet describe test data, test criteria and expected results. It is assumed the Vendor or Participant Under Test is familiar with the associated ONC test method.

# Robustness and Reliability Requirement

To satisfy the module criteria, it is expected that the Product-Under-Test is able to complete the testing requirements reliably, including repeat testing with the same result without error, and with a satisfactory level of robustness. This includes unexpected error messages produced through normal operation, multiple unintended restarts of the application or any other “buggy” facets of the product displayed while testing. These errors are record in the Additional Proctor Notes of the proctor sheet. Lack of reliability and robustness of design will result in failure of the module.

# Test Data and Tools

|  |  |
| --- | --- |
| **Test Data Source:** | ONC-Supplied: DG-Supplied: Developer-Supplied: |
| **Pre-Test Data Setup:**  Health IT developer should:   * Configure severity level to initially show ‘All Interactions’ (user will change this setting during test event). * Prepare the following combinations to be demonstrated on test day:   + High significance drug-drug interaction   + Low significance drug-drug interaction   + Drug-allergy interaction | |
| **Test Data:**  Developer-supplied. | |
| **Test Tools:**  Not applicable. | |

# Demonstrate Standards Support

|  |  |
| --- | --- |
| **Test Result:** | PASS:  FAIL:  No Attempt: |
| **Instructions:** There are no standards required for this criterion. | |

# DTR 170.315(a)(4)(i) – Drug-drug, Drug-allergy Interaction Checks for CPOE – Interventions

|  |  |
| --- | --- |
| **Test Result:** | PASS:  FAIL:  No Attempt: |
| **Instructions:**   * The user is automatically provided drug-drug and drug-allergy interventions when ordering a medication during CPOE. | |
| **Expected Test Result:**   * Health IT module must provide the drug-drug and drug-allergy intervention checks before the CPOE medication order is completed and acted upon. | |
| **Points to Remember:**   * This module is eligible for gap certification. * If health IT developer is also testing (a.1) CPOE-Medications, then developer may elect to perform the Drug-drug, drug-allergy interaction checks while testing module (a.1) CPOE-Medications. | |

**Test Procedures**

**1.1 Interventions: Drug-Drug**

|  |  |
| --- | --- |
|  | Health IT developer demonstrates the ability to adjust severity levels is limited to a specific set of users, or as a system administrative function. |
|  | Log in as authorized user and configure severity levels to display “all interactions” |
|  | Log in as authorized user with access to enter medication orders. Verify patient current medication and allergy list. Based on these elements, create:   * High significance drug-drug interaction * Low significance drug-drug interaction * Drug-allergy interaction |
|  | Proctor verifies the interaction checks are automatically produced prior to the completion of the medication order. |
|  | User will stop the medication ordering upon receiving the interventions so that the same drug(s) can be later ordered in in the next section |

<INSERT SCREEN SHOTS>

**1.3 Adjustments**

|  |  |
| --- | --- |
|  | Authorized user logs in and adjust the severity level to display only high significance interactions |
|  | User will re-demonstrate the drug-drug interactions already done above to verify severity level has been adjusted and only high significance interactions display. |
|  | Proctor verifies severity level for the drug-drug interaction demonstrated above was adjusted. |
|  | User logs in as unauthorized user to attempt to adjust severity levels. |
|  | Proctor verifies unauthorized user above cannot adjust severity levels. |

<INSERT SCREEN SHOTS>

# Appendix A: Testing Guide

*This appendix contains more details and background on the testing requirements, including explanation on underlying standards, notable issues and best practice suggestions.*

Rev 01-Mar-2016 Additions

* Intervention adjustment must be configurable by a user, even if it is an administrator user or change is fairly technical in nature (e.g. backend configuration files), and not “hard coded” or can only be adjusted by the vendor.
* It is not permissible to inactivate a specific active medication from the patient record to satisfy the requirement. The medication must remain active in the patient record, but only change the notification method of the EHR to modify the alert status.

# Appendix B: ONC Criteria and Standards

*This appendix contains copy of the relevant ONC criteria and standards for this proctor sheet as a reference. In the event of a discrepancy with the ONC Final Rule, the ONC Final Rule takes precedence.*

**§170.315(4) *Drug-drug, drug-allergy interaction checks for CPOE—*** (i) *Interventions.* Before a medication order is completed and acted upon during computerized provider order entry (CPOE), interventions must automatically indicate to a user drug-drug and drug-allergy contraindications based on a patient's medication list and medication allergy list.

(ii) *Adjustments.* (A) Enable the severity level of interventions provided for drug-drug interaction checks to be adjusted.

(B) Limit the ability to adjust severity levels in at least one of these two ways:

(*1*) To a specific set of identified users.

(*2*) As a system administrative function.

# Change Log

|  |  |
| --- | --- |
| Revision | Change Description |
| 15-Sept-2017 | Replaced DG-supplied test data with developer-supplied. |
| 01-Mar-2016 | Initial Release |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

**About Drummond Group LLC**

Drummond Group LLC is a global software test and certification lab that serves a wide range of vertical industries.  In healthcare, Drummond Group tests and certifies Controlled Substance Ordering Systems (CSOS), Electronic Prescription of Controlled Substances (EPCS) software and processes, and Electronic Health Records (EHRs) – designating the trusted test lab as the only third-party certifier of all three initiatives designed to move the industry toward a digital future. Founded in 1999, and accredited for the Office of the National Coordinator Health IT Certification Program as an Authorized Certification Body (ACB) and an Authorized Test Lab (ATL), Drummond Group continues to build upon its deep experience and expertise necessary to deliver reliable and cost-effective services. For more information, please visit <http://www.drummondgroup.com> or email [ehr@drummondgroup.com](mailto:ehr@drummondgroup.com)

END OF DOCUMENT